MRRPhysical AI
intelligence
← Company intelligence

Robot maker · registered

Wandercraft

Corporate markethumanoidCurated record
wandercraft.eu

Exoskeleton pioneer whose self-balancing bipedal control (from its Atalante X rehab exoskeleton and Eve personal exoskeleton) underpins Calvin-40, an AI-driven industrial humanoid for heavy load handling on assembly lines; Renault Group is its first commercial Calvin-40 customer and a Series D investor.

HeadquartersParis, FR
Founded2012
Corporate funding$146M
Team51-200
Deployments9
Open roles0
01

Company overview

Identity and operating footprint

Company typeRobot maker
Market segmentCorporate
StageSeries D
FoundersMatthieu Masselin, Nicolas Simon, Alexandre Boulanger, Jean-Louis Constanza
Regions servedEU, US
Countries deployedFR
Service footprintHQ Paris FR; US office in New York; Atalante X deployed in 100+ hospitals and rehabilitation centers across 15+ countries
Last reviewed2026-07-05
MX

Robot models

Specifications remain vendor-claimed

Machinehumanoid

Atalante X

  • Self-balancing medical exoskeleton for hospital rehabilitation training, FDA-cleared with extended indications

    vendor-defined clinical rehabilitation exoskeleton

    Claim source
Machinehumanoid

Calvin-40

  • Can lift up to ~40 kg (90 lb) several hundred times a day without rest

    vendor-claimed repeated lift payload and duty cycle

    Claim source
  • Designed for continuous use of 8 to 22 hours per day with a target fail rate < 1/1000

    vendor-defined operational duty cycle and reliability target

    Claim source
Machinehumanoid

Eve

  • First self-balancing personal exoskeleton, hands-free and usable without crutches (US clinical trial enrollment underway)

    vendor-defined personal mobility exoskeleton

    Claim source
DP

Deployment log

Announced and cited only

AnnouncedCustomerSiteCountryCountEvidence
2026-06-25National Seating & Mobility (NSM)CRT distribution partner / Eve exoskeleton launchUSNot disclosedAnnouncement
2025-12-10The Shepherd Centerclinical use — NCT07128901UnNot disclosedAnnouncement
2025-11-25Sapaindustrial manufacturingFRNot disclosedAnnouncement
2025-11-03Rancho Research Instituterehabilitation-centerUSNot disclosedAnnouncement
2025-10-01Brigham and Women's Hospitalclinical use — NCT07220733UnNot disclosedAnnouncement
2025-07-09Moody Neurorehabilitation InstituteneurorehabilitationUSNot disclosedAnnouncement
2025-06-06Renault Groupautomotive assembly plant (Douai)FRNot disclosedAnnouncement
2023-10-12Kessler FoundationhospitalUS1Announcement
2023-08-07Institut Guttmannclinical use — NCT07556809SpNot disclosedAnnouncement
CA

Funding history

Publicly announced rounds

Investors on recordRenault GroupBpifranceQuadrant ManagementTeampact VenturesLBO France
TL

Company timeline

Milestones and announcements

2026-10-01Wandercraft acquires Ekso Bionics from ChronoScale Holdings subsidiary (terms undisclosed, closed at announcement)HIT Consultant
2026-08-03FDA clearance for Eve self-balancing personal exoskeleton; US commercial launch begins Sep 2026MassDevice
2026-03-10Renault announces plan to deploy 350 Calvin-40 humanoids across manufacturing facilities within 18 months; Douai plant already operational on tire handling tasksHumanoids Daily
2025-11-03FDA grants second indication extension for Atalante X covering high-level SCI (C4–L5) and multiple sclerosis; deployed 100+ rehab centers, 1M+ steps/monthGlobeNewswire
2025-06-11Raised $75M Series D led by Renault Group and Bpifrance for global Calvin-40 and Eve expansionWandercraft
2024-02-13Atalante X receives second FDA clearance for spinal cord injury rehabilitation (T5–L5)GlobeNewswire
2023-01-23Atalante X receives first FDA clearance (stroke/CVA rehabilitation)Newswire
2022-01-19Raised $45M Series C led by Quadrant Management for US expansion and Eve personal exoskeleton developmentTechCrunch
SC

Source ledger

25 unique public sources

01
Wandercraft announces Series D Round, bringing $75M in total funding secured for global acceleration of AI-powered roboticsGlobeNewswire / Wandercraft · retrieved 2026-07-05
02
French robotic exoskeleton maker Wandercraft eyes US expansion with $45M Series CTechCrunch · retrieved 2026-07-05
03
EU project: Memory of MotionCORDIS (European Commission) · retrieved 2026-07-05
04
XAnge, Idinvest et al. in €15m Wandercraft Series B (€15M EUR converted at ~1.19 EUR/USD)Unquote · retrieved 2026-07-05
05
Wandercraft et son exosquelette franchissent un pas avec une levée de 4 millions d'eurosMaddyness · retrieved 2026-07-05
06
Atalante X Rehabilitation ExoskeletonWandercraft
07
Wandercraft unveils Calvin, new industrial humanoid, and Renault partnershipThe Robot Report
08
Calvin-40 Industrial HumanoidWandercraft
09
Wandercraft - AI-powered roboticsWandercraft
10
Wandercraft Names National Seating & Mobility the Exclusive CRT Distribution Partner for Eve Personal ExoskeletonGlobeNewswire · retrieved 2026-07-05
11
Lower-Limb Exoskeleton Technology for Non-Ambulatory Individuals With Spinal Cord InjuryClinicalTrials.gov · retrieved 2026-07-28
12
Wandercraft and SAPA Announce Deployment Partnership to Implement and Scale Deployment of Calvin-40Humanoid Robotics Technology · retrieved 2026-07-05
13
Wandercraft Gains Second FDA Indication Extension for Atalante X in Less Than Two YearsGlobeNewswire · retrieved 2026-07-28
14
Safety and Feasibility of a Self-Balancing Exoskeleton in the Thoracic Surgical ICU (HEART)ClinicalTrials.gov · retrieved 2026-07-28
15
Moody Neurorehabilitation Institute Acquires Wandercraft's Atalante X to Transform Care for Complex PatientsWandercraft · retrieved 2026-07-05
16
Renault Group finalises a strategic partnership with WandercraftRenault Group · retrieved 2026-07-05
17
Wandercraft announces launch of US commercial operations with the start of Atalante X research at Kessler FoundationGlobeNewswire · retrieved 2026-07-28
18
Exoskeleton Gait Training in Guillain-Barré Syndrome (Atalante GBS)ClinicalTrials.gov · retrieved 2026-07-28
19
Wandercraft acquires Ekso BionicsHIT Consultant
20
Wandercraft's self-balancing Eve exoskeleton begins US launchMassDevice
21
Renault to Deploy 350 Wandercraft Calvin Humanoids in Industrial Speed RunHumanoids Daily
22
Wandercraft Gains Second FDA Indication Extension for Atalante XGlobeNewswire
23
Wandercraft announces Series D RoundWandercraft
24
Wandercraft's exoskeleton receives second FDA clearance for spinal cord injury rehabilitationGlobeNewswire
25
Wandercraft Receives FDA Clearance for AtalanteNewswire